Global Percutaneous Renal Denervation (RDN) Treatment Market Growth 2025-2031
Description
The global Percutaneous Renal Denervation (RDN) Treatment market size is predicted to grow from US$ 1295 million in 2025 to US$ 10555 million in 2031; it is expected to grow at a CAGR of 41.9% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Percutaneous Renal Denervation (RDN) treatment is a minimally invasive procedure that involves the insertion of a catheter through the femoral artery to deliver targeted energy—via radiofrequency, ultrasound, or chemical agents—to disrupt the renal sympathetic nerves surrounding the renal arteries. By reducing sympathetic nervous system activity, RDN aims to achieve sustained blood pressure reduction, particularly in patients with resistant hypertension. This therapy is also being investigated for other conditions associated with sympathetic overactivity, such as heart failure and arrhythmias, due to its safety, repeatability, and long-term efficacy.
United States market for Percutaneous Renal Denervation (RDN) Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Percutaneous Renal Denervation (RDN) Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Percutaneous Renal Denervation (RDN) Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Percutaneous Renal Denervation (RDN) Treatment players cover Medtronic, SoniVie, ReCor Medical（Otsuka）, Abbott, Boston Scientific, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Percutaneous Renal Denervation (RDN) Treatment Industry Forecast” looks at past sales and reviews total world Percutaneous Renal Denervation (RDN) Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Percutaneous Renal Denervation (RDN) Treatment sales for 2025 through 2031. With Percutaneous Renal Denervation (RDN) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Percutaneous Renal Denervation (RDN) Treatment industry.
This Insight Report provides a comprehensive analysis of the global Percutaneous Renal Denervation (RDN) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Percutaneous Renal Denervation (RDN) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Percutaneous Renal Denervation (RDN) Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Percutaneous Renal Denervation (RDN) Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Percutaneous Renal Denervation (RDN) Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Percutaneous Renal Denervation (RDN) Treatment market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Radiofrequency Ablation
Ultrasound Ablation
Other
Segmentation by Application:
Resistant Hypertension
Patients with Essential Hypertension
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Medtronic
SoniVie
ReCor Medical（Otsuka）
Abbott
Boston Scientific
Ablative Solutions
Shanghai Bio-heart
Symap Medical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Percutaneous Renal Denervation (RDN) Treatment market?
What factors are driving Percutaneous Renal Denervation (RDN) Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Percutaneous Renal Denervation (RDN) Treatment market opportunities vary by end market size?
How does Percutaneous Renal Denervation (RDN) Treatment break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Percutaneous Renal Denervation (RDN) treatment is a minimally invasive procedure that involves the insertion of a catheter through the femoral artery to deliver targeted energy—via radiofrequency, ultrasound, or chemical agents—to disrupt the renal sympathetic nerves surrounding the renal arteries. By reducing sympathetic nervous system activity, RDN aims to achieve sustained blood pressure reduction, particularly in patients with resistant hypertension. This therapy is also being investigated for other conditions associated with sympathetic overactivity, such as heart failure and arrhythmias, due to its safety, repeatability, and long-term efficacy.
United States market for Percutaneous Renal Denervation (RDN) Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Percutaneous Renal Denervation (RDN) Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Percutaneous Renal Denervation (RDN) Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Percutaneous Renal Denervation (RDN) Treatment players cover Medtronic, SoniVie, ReCor Medical（Otsuka）, Abbott, Boston Scientific, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Percutaneous Renal Denervation (RDN) Treatment Industry Forecast” looks at past sales and reviews total world Percutaneous Renal Denervation (RDN) Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Percutaneous Renal Denervation (RDN) Treatment sales for 2025 through 2031. With Percutaneous Renal Denervation (RDN) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Percutaneous Renal Denervation (RDN) Treatment industry.
This Insight Report provides a comprehensive analysis of the global Percutaneous Renal Denervation (RDN) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Percutaneous Renal Denervation (RDN) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Percutaneous Renal Denervation (RDN) Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Percutaneous Renal Denervation (RDN) Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Percutaneous Renal Denervation (RDN) Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Percutaneous Renal Denervation (RDN) Treatment market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Radiofrequency Ablation
Ultrasound Ablation
Other
Segmentation by Application:
Resistant Hypertension
Patients with Essential Hypertension
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Medtronic
SoniVie
ReCor Medical（Otsuka）
Abbott
Boston Scientific
Ablative Solutions
Shanghai Bio-heart
Symap Medical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Percutaneous Renal Denervation (RDN) Treatment market?
What factors are driving Percutaneous Renal Denervation (RDN) Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Percutaneous Renal Denervation (RDN) Treatment market opportunities vary by end market size?
How does Percutaneous Renal Denervation (RDN) Treatment break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
89 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Percutaneous Renal Denervation (RDN) Treatment by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Percutaneous Renal Denervation (RDN) Treatment by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
